TELMISARTAN 40 - Rohm Labs

Telmisartan, an angiotensin II receptor blocker (ARB), is well-known for its effectiveness in managing hypertension and cardiovascular health. Recently, its role has expanded into oncology, with studies indicating it may have antitumor effects, particularly against esophageal squamous cell carcinoma (ESCC). In both in vitro and in vivo models, telmisartan was shown to inhibit ESCC cell proliferation, largely by inducing S-phase cell-cycle arrest. This mechanism, marked by decreased expression of cyclin A2 and CDK2, highlights telmisartan's potential to halt cancer cell growth without promoting apoptosis. This finding, coupled with its ability to downregulate cell proliferation signals like ErbB3, underscores telmisartan's emerging value in cancer therapy.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about TELMISARTAN 40 by Rohm Labs, consult with your doctor or healthcare professional.